Date: 28th July, 2026

To	To
The Listing Department **National Stock Exchange of India Limited** Exchange Plaza, Bandra – Kurla Complex Bandra (East) Mumbai – 400 051 ***Stock Code : INDOCO***	The Listing Department **Bombay Stock Exchange Limited** Floor 25, P. J. Towers, Dalal Street, Mumbai – 400 001 ***Stock Code : 532612***

Dear Sir/Madam,

Subject: Outcome of Board Meeting held on 28th July, 2026

Pursuant to the Regulation 30 read with Schedule III and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that the Board of Directors of the Company at its Meeting held today i.e. 28th July, 2026 has inter-alia considered and approved Unaudited Standalone and Consolidated Financial Results for the Quarter Ended 30th June, 2026 along with the Limited Review Report with unmodified opinion on the aforesaid Unaudited Financial Results.

Please find enclosed copies of the following:

a. Unaudited Standalone and Consolidated Financial Results for the Quarter Ended 30th June, 2026 as per Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
b. Limited Review Report with unmodified opinion issued by our Statutory Auditors M/s. Gokhale & Sathe, Chartered Accountants.
c. Press Release.

The Board Meeting commenced today at 10:45 a.m. and concluded at 11:45 a.m.

You are requested to kindly take the same on record.

Thanking you,
Yours faithfully,
For Indoco Remedies Limited

RAMANATHAN HARIHARAN Digitally signed by RAMANATHAN HARIHARAN Date: 2026.07.28 11:49:58 +05'30'

INDOCO REMEDIES LIMITED MUMBAI

Ramanathan Hariharan
Company Secretary & Head- Legal

INDOCO REMEDIES LIMITED

Regd. Office : Indoco House, 166, CST Road, Kalina,Santacruz (E), Mumbai 400 098.
Tel:+91-22-26541851/55 Fax:+91-22-26520787 Email: compliance.officer@indoco.com
Website:www.indoco.com CIN:L85190MH1947PLC005913

STATEMENT OF STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE 2026

(Rs. In Lakhs)

S.No.	Particulars	Quarter ended 30.06.2026 (Unaudited)	Quarter ended 31.03.2026 (Audited)	Quarter ended 30.06.2025 (Unaudited)	Year ended 31.03.2026 (Audited)
1	**Income from Operations**				
	(a) Revenue from Operations	40,812	42,906	38,561	1,63,354
	(b) Other Operating Income	85	2,007	870	5,253
	Total Income from Operations (Net) (a+b)	**40,897**	**44,913**	**39,431**	**1,68,607**
2	**Other Income**	447	1,035	558	2,964
3	**Total Income (1+2)**	**41,344**	**45,948**	**39,989**	**1,71,571**
4	**Expenses**				
	(a) Cost of materials consumed	8,599	9,825	8,777	35,323
	(b) Purchases of stock-in-trade	3,959	2,908	3,923	14,012
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	1,487	1,058	(583)	720
	(d) Employee Benefits expense	9,065	10,098	9,850	39,363
	(e) Research & Development Expense	1,854	1,776	2,167	7,954
	(f) Other Expenses	11,712	12,945	13,815	55,520
	(g) Finance Costs	2,275	2,273	2,361	8,850
	(h) Depreciation and Amortization expense	2,805	2,671	2,520	10,690
	Total Expenses	**41,756**	**43,554**	**42,830**	**1,72,432**
5	**Profit / (Loss) Before Exceptional Items and Tax (3-4)**	**(412)**	**2,394**	**(2,841)**	**(861)**
6	Exceptional Items (*)	9,734	368	-	(286)
7	**Profit Before Tax (5+6)**	**9,322**	**2,762**	**(2,841)**	**(1,147)**
8	**Tax Expenses** - Current	1,056	292	-	292
	- Deferred	34	(265)	(34)	(873)
	- MAT Credit Adjustments	-	-	-	-
	Total Tax Expenses	**1,090**	**27**	**(34)**	**(581)**
9	**Profit for the period (7-8)**	**8,232**	**2,735**	**(2,807)**	**(566)**
10	**Other Comprehensive Income**				
a	i) Items that will not be reclassified to profit and loss	(60)	403	(75)	178
	ii) Income tax on relating to this item	15	(102)	19	(45)
b	i) Items that may be reclassified to profit or loss	-	(335)	129	-
	ii) Income tax on relating to this item	-	84	(32)	-
	Total Other Comprehensive Income	**(45)**	**50**	**41**	**133**
11	**Total Comprehensive income for the year (9+10)**	**8,187**	**2,785**	**(2,766)**	**(433)**
12	Paid up Equity Share Capital (Face value Rs. 2/- each)	1,846	1,846	1,845	1,846
13	Other Equity				1,08,073
14	Earnings per share (of Rs. 2/- each)				
	(a) Basic- in Rs.	8.92	2.96	(3.04)	(0.61)
	(b) Diluted- in Rs.	8.92	2.96	(3.04)	(0.61)

Notes:

1 The unaudited Standalone Results for the Quarter ended 30th June, 2026 have been reviewed by the Audit committee and approved by the Board of Directors of the Company at its meeting held on 28th July, 2026. The Statutory Auditors have expressed an Unmodified Audit opinion on these unaudited Standalone Financial Results.

2 The figures for corresponding previous periods have been restated / regrouped wherever necessary, to make them comparable.

3 The company has only one primary reportable segment of activity, namely, Pharmaceuticals.

4 Net Sales and Income from Operations as per Secondary Segment (Geographical) is as follows:

Net Sales and Income from Operations	Quarter ended 30.06.2026 (Unaudited)	Quarter ended 31.03.2026 (Audited)	Quarter ended 30.06.2025 (Unaudited)	Year ended 31.03.2026 (Audited)
India	22,775	19,363	22,255	89,413
Outside India	18,037	23,543	16,306	73,941
Total	**40,812**	**42,906**	**38,561**	**1,63,354**

5 The statutory auditors of the company have carried out limited review of the financial results for the quarter ended 30th June, 2026.

6 Figures for the quarter ended 31.3.2026 represents the difference between audited figures in respect of the full financial year and published figures for the period ended 31.12.2025 (limited reviewed).

7 (*) The Company completed the slump sale of its Ophthalmic Business Division to Sunways (India) Private Limited. The gain on sale of Rs 9,734 Lakhs has been recognized as an Exceptional Item in the Statement of Profit or Loss.

By Order of the Board
For Indoco Remedies Ltd

INDOCO REMEDIES LTD. MUMBAI

Aditi Panandikar
Managing Director

Place : Mumbai
Date : July 28, 2026

gokhale & sathe
(regd.)
chartered accountants

304/308/309/311,udyog mandir no.1,
7-c, bhagoji keer marg,mahim,
mumbai - 400 016,maharashtra,india.

Independent Auditors' Limited Review Report on quarterly unaudited standalone financial results of Indoco Remedies Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To
The Board of Directors,
Indoco Remedies Limited

1 We have reviewed the accompanying statement of unaudited standalone financial results ("the Statement") of Indoco Remedies Limited ('the Company') for the quarter ended 30 June 2026 being submitted by the Company pursuant to the requirement of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements), Regulation 2015 as amended.

2 This Statement, which is the responsibility of the Company's management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.

3 We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial results are free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4 Attention is drawn to the fact that the figures for the three months ended 31 March 2026 as reported in these unaudited standalone financial results are the balancing figures between audited figures in respect of the full previous financial year and the published year to date figures up to the third quarter of the previous financial year. The figures up to the end of the third quarter of the previous financial year had only been reviewed and not subjected to audit.

GOKHALE & SATHE MUMBAI FIRM No. 103264W CHARTERED ACCOUNTANTS

5 Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable Indian Accounting Standards specified under section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

6 **Emphasis of Matter**

We draw attention to the Note on Non-current Financial Investment in Standalone financial statements -

FPP Holding LLC

For the quarter ended 30 June 2026, the Company earned a net profit of Rs. 300.89 lakhs. Notwithstanding the profit earned during the quarter, the Company continued to have a negative net worth of Rs. 3,822.60 lakhs as at 30 June 2026.

The above condition indicate the existence of a material uncertainty that may cast significant doubt on the ability of the respective company to continue as going concern. In accordance with the requirements of Ind AS 36, Impairment of Assets, the Group has carried out impairment testing of the carrying amounts of its investments in these subsidiaries, given the erosion of their net worth. Based on the impairment assessment performed by management, which included review of long-term business plans, cash flow forecasts, and other relevant assumptions, the recoverable amounts of these investments were estimated to exceed their respective carrying values. Accordingly, no impairment provision has been considered necessary by the management at this stage.

Our opinion is not modified in respect of this matter.

For Gokhale & Sathe,
Chartered Accountants
Firm Registration No.: 103264W

GOKHALE & SATHE MUMBAI FIRM No. 103264W CHARTERED ACCOUNTANTS

Atul Kale
Partner
Membership Number -109947
UDIN: 26109947PPURQL6983
Place: Mumbai
Date: 28th July 2026

INDOCO REMEDIES LIMITED
Regd. Office : Indoco House, 166, CST Road, Kalina,Santacruz (E), Mumbai 400 098.
Tel:+91-22-26541851/55 Fax:+91-22-26520787 Email: compliance.officer@indoco.com
Website:www.indoco.com CIN:L85190MH1947PLC005913

STATEMENT OF CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2026

(Rs. In Lakhs)

S.No.	Particulars	Quarter ended 30.06.2026 (Unaudited)	Quarter ended 31.03.2026 (Audited)	Quarter ended 30.06.2025 (Unaudited)	Year ended 31.03.2026 (Audited)
1	**Income from Operations**				
	(a) Revenue from Operations	46,622	45,590	43,086	1,79,294
	(b) Other Operating Income	128	1,971	881	5,238
	Total Income from Operations (Net) (a+b)	**46,750**	**47,561**	**43,967**	**1,84,532**
2	**Other Income**	218	(4)	163	333
3	**Total Income (1+2)**	**46,968**	**47,557**	**44,130**	**1,84,865**
4	**Expenses**				
	(a) Cost of materials consumed	10,458	10,918	10,553	42,560
	(b) Purchases of stock-in-trade	3,989	3,252	3,923	14,355
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	1,358	(69)	(979)	(2,741)
	(d) Employee Benefits expense	10,141	10,941	10,702	42,569
	(e) Research & Development Expense	1,854	1,776	2,166	7,954
	(f) Other Expenses	14,848	15,772	15,849	65,655
	(g) Finance Costs	2,829	4,592	2,612	12,225
	(h) Depreciation and Amortization expense	3,453	3,249	2,970	12,645
	Total Expenses	**48,930**	**50,431**	**47,796**	**1,95,222**
5	**Profit Before Exceptional Items and Tax (3-4)**	**(1,962)**	**(2,874)**	**(3,666)**	**(10,357)**
6	Exceptional Items (*)	9,734	374	-	(294)
7	**Profit / (Loss) Before Tax (5+6)**	**7,772**	**(2,500)**	**(3,666)**	**(10,651)**
8	**Tax Expenses** - Current	1,059	296	-	302
	- Deferred	169	(428)	(31)	(1,083)
	- MAT Credit Adjustments	-	-	-	-
	Total Tax Expenses	**1,228**	**(132)**	**(31)**	**(781)**
9	**Profit for the period (7-8)**	**6,544**	**(2,368)**	**(3,635)**	**(9,870)**
10	**Other Comprehensive Income**				
a	i) Items that will not be reclassified to profit and loss	(62)	414	(77)	184
	ii) Income tax on relating to this item	15	(103)	19	(46)
b	i) Items that may be reclassified to profit or loss	118	857	87	1,262
	ii) Income tax on relating to this item	(3)	(24)	(45)	(138)
	Total Other Comprehensive Income	**68**	**1,144**	**(16)**	**1,262**
11	**Total Comprehensive income for the year (9+10)**	**6,612**	**(1,224)**	**(3,651)**	**(8,608)**
	Profit attributable to :				
	Equity Shareholders of the Company	6,499	(2,164)	(3,579)	(9,515)
	Non-Controlling Interest - Profit / (Loss)	45	(204)	(56)	(355)
		6,544	**(2,368)**	**(3,635)**	**(9,870)**
	Other comprehensive income is attributable to:				
	Equity Shareholders of the Company	68	1,144	(16)	1,262
	Non-Controlling Interest	-	-	-	-
		68	**1,144**	**(16)**	**1,262**
	Total comprehensive income is attributable to:				
	Equity Shareholders of the Company	6,567	(1,020)	(3,595)	(8,253)
	Non-Controlling Interest - Profit / (Loss)	45	(204)	(56)	(355)
		6,612	**(1,224)**	**(3,651)**	**(8,608)**
12	Paid up Equity Share Capital (Face value Rs. 2/- each)	1,846	1,846	1,845	1,846
13	Other Equity				92,082
14	Earnings per share (of Rs. 2/- each)				
	(a) Basic- in Rs.	7.09	(2.57)	(3.94)	(10.70)
	(b) Diluted- in Rs.	7.09	(2.56)	(3.94)	(10.69)

Notes :

1 The unaudited Consolidated Results for the Quarter ended 30th June, 2026, have been reviewed by the Audit committee and approved by the Board of Directors of the Company at its meeting held on 28th July, 2026. The Statutory Auditors have expressed an Unmodified Audit opinion on these unaudited Consolidated Financial Results.

2 The figures for corresponding previous periods have been restated / regrouped wherever necessary, to make them comparable.

3 The company has only one primary reportable segment of activity, namely, Pharmaceuticals.

4 Net Sales and Income from Operations as per Secondary Segment (Geographical) is as follows:

(Rs. In Lakhs)

Net Sales and Income from Operations	Quarter ended 30.06.2026 (Unaudited)	Quarter ended 31.03.2026 (Audited)	Quarter ended 30.06.2025 (Unaudited)	Year ended 31.03.2026 (Audited)
India	31,177	24,714	27,783	1,12,412
Outside India	15,445	20,876	15,303	66,882
Total	**46,622**	**45,590**	**43,086**	**1,79,294**

5 The Consolidated Financial Results includes the Results of the following Companies

Name of the Company	% of Shareholding	Consolidated as
Xtend Industrial Designers & Engineers Pvt. Ltd.	100	Subsidiary
Indoco Remedies Czech S R O	100	Subsidiary
Indoco Remedies UK Ltd.	100	Subsidiary
Warren Remedies Private Limited	100	Subsidiary
FPP Holding Company, LLC	85	Subsidiary

6 Figures for the quarter ended 31.3.2026 represents the difference between audited figures in respect of the full financial year and published figures for the period ended 31.12.2025 (limited reviewed).

7 (*) The Company completed the slump sale of its Ophthalmic Business Division to Sunways (India) Private Limited. The gain on sale of Rs 9,734 Lakhs has been recognized as an Exceptional Item in the Statement of Profit or Loss.

INDOCO REMEDIES LTD. MUMBAI

By Order of the Board
For Indoco Remedies Ltd

Aditi Panandikar
Managing Director

Place : Mumbai
Date : July 28, 2026

gokhale & sathe
(regd.)
chartered accountants

304/308/309/311,udyog mandir no.1,
7-c, bhagoji keer marg,mahim,
mumbai - 400 016,maharashtra,india.

Independent Auditors' Limited Review Report on quarterly unaudited consolidated financial results of Indoco Remedies Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To
The Board of Directors,
Indoco Remedies Limited

1 We have reviewed the accompanying statement of unaudited consolidated financial results of Indoco Remedies Limited (hereinafter referred to as the "Holding Company") and its subsidiaries (the Holding Company and its subsidiaries together referred to as 'the Group') for the quarter ended 30 June 2026, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

2 This Statement, which is the responsibility of the Holding Company's Management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to issue a report on the statement based on our review.

3 We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4 This statement includes the results of the following entities:
a) Xtend Industrial Designers and Engineers Private Limited
b) Indoco Remedies Czech sro
c) Indoco Remedies UK Limited
d) Warren Remedies Private Limited
e) FPP Holding Company, LLC (wef 5 June 2023)
f) Florida Pharmaceuticals Products LLC (wholly owned subsidiary of FPP Holding Company, LLC)

GOKHALE & SATHE MUMBAI FIRM No. 103264W CHARTERED ACCOUNTANTS

5 Attention is drawn to the fact that the figures for the three months ended 31 March 2026 as reported in these unaudited consolidated financial results are the balancing figures between audited figures in respect of the full previous financial year and the published year to date figures up to the third quarter of the previous financial year. The figures up to the end of the third quarter of the previous financial year had only been reviewed and not subjected to audit.

6 Based on our review and procedures performed as stated in paragraph 3 above and based on consideration of the review reports of the auditors referred in paragraph no 7 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable Indian Accounting Standards specified under section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other recognised accounting practices and policies, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

7 **Emphasis of Matter**

We draw attention to the Note on Non-current Financial Investment in Consolidated financial statements -

FPP Holding LLC

For the quarter ended 30 June 2026, the Company earned a net profit of Rs. 300.89 lakhs. Notwithstanding the profit earned during the quarter, the Company continued to have a negative net worth of Rs. 3,822.60 lakhs as at 30 June 2026.

The above condition indicate the existence of a material uncertainty that may cast significant doubt on the ability of the respective company to continue as going concern. In accordance with the requirements of Ind AS 36, Impairment of Assets, the Group has carried out impairment testing of the carrying amounts of its investments in these subsidiaries, given the erosion of their net worth. Based on the impairment assessment performed by management, which included review of long-term business plans, cash flow forecasts, and other relevant assumptions, the recoverable amounts of these investments were estimated to exceed their respective carrying values. Accordingly, no impairment provision has been considered necessary by the management at this stage.

GOKHALE & SATHE
MUMBAI
FIRM No. 103264W
CHARTERED ACCOUNTANTS

8 Other Matter

1. We did not review the interim financial statements of the subsidiaries included in the statement of unaudited consolidated financial results, whose unaudited financial statements reflect total revenues of Rs. 9.69 Lakhs, and total profit after tax of Rs. 7.84 Lakhs for the quarter ended 30 June 2026, as considered in the Statement. This financial information has been reviewed by other auditors whose reports has been furnished to us by the management and our conclusion on the Statements, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries is based solely on the report of other auditors and the procedures performed by us as stated in paragraph 3 above.

2. The unaudited consolidated financial results also include the financial information of 3 foreign subsidiaries and 1 step down wholly owned subsidiary, which have not been reviewed, whose financial information reflects total revenues of Rs. 4,918.96 Lakhs and total net profit after tax of Rs. 300.69 Lakhs for the quarter ended 30 June 2026, as considered in the Statement. According to the information and explanations given to us by the Management, these interim financial information/financial results are not material to the Group.

Our opinion is not modified in respect of these matters.

For Gokhale & Sathe,
Chartered Accountants
Firm Registration Number: 103264W

Atul Kale
Partner
Membership Number: 109947
UDIN: 26109947ZMURHA6135
Place: Mumbai
Date: 28th July 2026

GOKHALE & SATHE
MUMBAI
FIRM No. 103264W
CHARTERED ACCOUNTANTS

PRESS RELEASE

Indoco Q1 revenues grew 6 % YoY

Mumbai, Jul 28, 2026: During the first quarter of FY 2026-27, revenues of Indoco Remedies are at ₹ 4,081 mn, as against ₹3856 mn, same quarter last year. EBIDTA to net sales for the quarter is 10.3 % at ₹ 422 mn, compared to 3.8 % at ₹ 148 mn, same quarter last year.

Commenting on the results, **Ms. Aditi Panandikar, Managing Director, Indoco Remedies Ltd**., said, “The first quarter of the financial year 2026-27 reflects the continued execution of our long-term strategy focused on deliverables from our core businesses despite a dynamic operating environment. The growth in this quarter is due to the resilient Domestic Formulation business, while our international formulations and API businesses continued to make steady progress.”

About Indoco Remedies Limited:

Indoco is a fully integrated, research-oriented pharmaceutical company with a strong global presence. The Company’s turnover is US$ 175 million with human capital of over 6000 employees, including over 300 skilled scientists and field staff who are the strength of the organization.

The Company has 10 manufacturing facilities, 6 for FDFs and 4 for APIs, supported by a state-of-the-art R&D Centre and a CRO facility. The facilities have been approved by most of the Regulatory Authorities including USFDA and UK-MHRA. Indoco develops and manufactures a wide range of pharmaceutical products for the Indian and international markets. It generates more than 109 million prescriptions annually from over 2,50,000 doctors belonging to various specialties. Indoco has 10 domestic marketing divisions, a strong brand portfolio in various therapeutic segments including Gastro-intestinal, Respiratory, Anti-Infectives, Stomatologicals, Nutritionals, Cardiovascular, Anti-Diabetics, Pain Management, Gynaecology, etc. Top Indoco brands include Cyclopam, Febrex Plus, ATM, Rexidin M, Karvol Plus, Oxipod, Cital, Sensodent-K, Cital-Uti, Dropizin, Homide, Dentogel, Oxipod CV, Turbocort, Febrex, Cloben G, Tuspel LS, Noxa, MCBM 69, etc. On the international front, Indoco has tie-ups with large generic companies across the globe.

For more details on Indoco, you may visit www.indoco.com

For investor relations queries please contact:

Contact- +91 22 68321400
Email: Ninad.Paradkar@indoco.com / corpcom@indoco.com